Pronostic de la myasthénie oculaire Analyse restrospective mutlticentre

Rubrique ouverte à tous en lecture seule.
POUR ACCEDER AUX NOMBREUX AUTRES FORUMS IL EST NECESSAIRE DE S'INSCRIRE (fonction M'enregistrer en haut à droite de l'écran).
Répondre
Avatar de l’utilisateur

Auteur du sujet
Pboulanger
Administrateur
Administrateur
Messages : 4694
Inscription : 02 févr. 2010 18:41
Localisation : La Chapelle en Serval F-60520
    Windows 8.1 Firefox
Genre :
Résidence : France
Zodiaque : Lion
Âge : 60
Contact :

Pronostic de la myasthénie oculaire Analyse restrospective mutlticentre

Message par Pboulanger » 20 sept. 2015 20:27

:hi:

Lu sur publimed http://www.ncbi.nlm.nih.gov/pubmed/25892018
Traduction disponible directement en cliquant en bas à droite de ce message sur notre forum
Image
Prognosis of Ocular Myasthenia Gravis: Retrospective Multicenter Analysis.
Nagia L1, Lemos J2, Abusamra K3, Cornblath WT4, Eggenberger ER5.

Abstract
  • PURPOSE:
    To calculate the rate and timing of conversion from ocular myasthenia gravis to generalized myasthenia gravis.

    DESIGN:
    Retrospective multicenter analysis.
  • SUBJECTS:
    Patients included in the study were diagnosed with ocular myasthenia gravis without the presence of generalized disease at onset.
  • METHODS:
    We conducted a retrospective multicenter analysis. We reviewed charts of 158 patients who met diagnostic criteria for ocular myasthenia gravis. Patients were divided into 2 subgroups: an immunosuppressant treatment group and a nonimmunosuppressant treatment group. Timing of conversion to generalized disease and duration of follow-up also was evaluated. Additional data such as clinical symptoms at presentation, laboratory test results, and chest imaging results also were recorded.
  • MAIN OUTCOME MEASURES:
    Conversion rates to generalized myasthenia at 2 years, effect of immunosuppression on conversion, and timing of conversion.
  • RESULTS:
    The 158-patient cohort included 76 patients who received immunosuppressant therapy; the remaining 82 patients did not. The overall conversion rate to generalized disease was 20.9%. At 2 years, generalized myasthenia developed in 8 of 76 patients in the treated group and in 15 of 82 patients in the nonimmunotherapy group (odds ratio, 0.52; 95% confidence interval, 0.20-1.32). Median time for conversion to generalized disease was 20 months in the nonimmunosuppressant group and 24 months in the immunosuppressant group. Conversion occurred after 2 years of symptom onset in 30% of patients.
  • CONCLUSIONS:
    Conversion rates from ocular to generalized myasthenia gravis may be lower than previously reported both in immunosuppressed and nonimmunosuppressed patients. A subset of patients may continue to convert to generalized disease beyond 2 years from onset of symptoms, and close monitoring should be continued.
Copyright © 2015 American Academy of Ophthalmology. Published by Elsevier Inc. All rights reserved.

Amicalement,
Image

Répondre

Revenir vers « Informations »

Qui est en ligne ?

Utilisateurs parcourant ce forum : Aucun utilisateur inscrit et 1 invité